GSK vs. BMY, REGN, VRTX, ZTS, SNY, TAK, PFE, ABT, NVS, and AZN
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Sanofi (SNY), Takeda Pharmaceutical (TAK), Pfizer (PFE), Abbott Laboratories (ABT), Novartis (NVS), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
Bristol-Myers Squibb (NYSE:BMY) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
GSK has a net margin of 14.62% compared to GSK's net margin of -13.50%. Bristol-Myers Squibb's return on equity of 51.54% beat GSK's return on equity.
In the previous week, Bristol-Myers Squibb had 15 more articles in the media than GSK. MarketBeat recorded 32 mentions for Bristol-Myers Squibb and 17 mentions for GSK. GSK's average media sentiment score of 0.70 beat Bristol-Myers Squibb's score of 0.49 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.5%. GSK pays an annual dividend of $1.47 per share and has a dividend yield of 3.3%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. GSK pays out 53.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Bristol-Myers Squibb presently has a consensus target price of $60.00, indicating a potential upside of 36.27%. Given GSK's higher possible upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than GSK.
Bristol-Myers Squibb received 268 more outperform votes than GSK when rated by MarketBeat users. Likewise, 66.87% of users gave Bristol-Myers Squibb an outperform vote while only 57.04% of users gave GSK an outperform vote.
Bristol-Myers Squibb has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Bristol-Myers Squibb has higher revenue and earnings than GSK. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Summary
Bristol-Myers Squibb beats GSK on 11 of the 20 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
